A 61-year-old Caucasian male with a history of end-stage renal disease on hemodialysis for four years underwent deceased donor kidney transplant. Alemtuzemab was chosen as the immunosuppression induction agent. Despite delayed graft function, the initial post-operative period was uneventful. On post-operative day 14, the patient developed a right upper extremity DVT and was started on a heparin drip. The following day, the patient developed marked thrombocytopenia. Heparin was discontinued secondary to a concern for HIT and an argatroban infusion was initiated. Additionally, he developed fevers and his clinical condition worsened.
On post-operative day 16, the patient developed myoclonic jerks and altered mental status requiring transfer to
On post-operative day 16, the patient developed myoclonic jerks and altered mental status requiring transfer to